

## Symeres acquires DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Nijmegen, The Netherlands, September 10, 2025 – Symeres, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announces the acquisition of DGr Pharma, a drug development-focused company, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients. The acquisition is supported by Keensight Capital (“Keensight”), one of the leading private equity managers dedicated to pan-European Growth Buyout<sup>[1]</sup> investments.

Founded in 2018 and based in the Netherlands, DGr Pharma specialises in pre-clinical and clinical regulatory strategy and consultancy for biotech and pharmaceutical partners working in early drug development. Its core services include chemical-pharmaceutical, non-clinical and clinical development planning, quality assurance, and regulatory submissions. DGr Pharma has deep expertise in small and large molecules including antibodies, ADCs and oligonucleotides. With a reputation for scientific rigor, DGr Pharma adds significant regulatory depth to the Symeres portfolio enabling it to deliver a more integrated solution across the full spectrum of drug discovery and development.

DGr Pharma’s pharmacokinetic data analysis services operate under Good Clinical Practice (GCP) and Good Laboratory Practice (GLP), expertise that aligns with Symeres’ integrated offering, including ADME<sup>[2]</sup>. The GLP status enhances data quality and regulatory readiness, giving Symeres’ clients a more efficient and reliable path to IND submission.

Guillaume Jetten, CEO of Symeres, commented: *“This acquisition strengthens our ability to offer truly integrated solutions across the drug discovery and development spectrum. DGr Pharma’s expertise enhances our scientific capabilities, allowing us to better support our clients’ evolving needs and reinforce Symeres’ position as a partner of choice in the global biopharma market.”*

Kees Groen, Founder and CEO of DGr Pharma, added: *“This is an exciting new chapter for DGr Pharma. Joining Symeres provides us with the opportunity to grow our reach and expand the value we bring to clients, particularly in early-stage development. We share Symeres’ commitment to high-quality science, long-term relationships and entrepreneurial ambition and we look forward to being part of the next phase of growth.”*

Amit Karna, Partner at Keensight Capital, concluded: *“We are proud to support Symeres with this specialized acquisition, which will extend the company’s capabilities into highly complementary services and attractive drug classes. We look forward to continuing to support the Symeres team as they selectively broaden the Company’s offering for their blue-chip biopharma clients.”*

---

<sup>[1]</sup> **Growth Buyout:** investment in profitable, private companies experiencing strong growth, in minority or majority positions, with or without leverage, using a flexible approach tailored to the needs of individual entrepreneurs, in order to finance organic growth projects, acquisition strategies or provide historic shareholders with liquidity.

<sup>[2]</sup> Absorption, distribution, metabolism, and excretion.

\*\*\*

### **About Symeres**

Symeres is a leading mid-sized transatlantic Contract Research Development and Manufacturing Organization (CRDMO) for drug discovery and development, operating across sites in the Netherlands, the Czech Republic, Finland, and the US. The company combines proven expertise, adaptive thinking and attentive collaboration for small molecule and other drug modalities to realize the full value of transformative therapies from inception to IND. Services span from preclinical hit finding all the way to the delivery of early clinical phase drug substance API.

[www.symeres.com](http://www.symeres.com)

### **About DGr Pharma**

DGr Pharma aims to facilitate a fast and high-quality drug development process in close cooperation with the preclinical and clinical R&D departments of pharmaceutical and biotech companies through consultancy and contract research services. DGr Pharma provides support in early phase drug development with a focus on Toxicology, PK, Clinical Pharmacology, CMC and Regulatory Affairs support. Along with the PK expertise, they also provide the service of stand-alone non-compartmental PK analyses. DGr Pharma employs people with extensive industrial and/or regulatory experience. The extensive track record provides a strong basis for success.

[www.dgrpharma.com](http://www.dgrpharma.com)

### **About Keensight Capital**

Keensight Capital ("Keensight"), one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. With over 25 years of experience and €5.5bn of assets under management, Keensight Capital's team of seasoned professionals leverages their differentiated private equity experience to invest in profitably growing companies generating revenues in the range of €10 million to €400 million. Drawing on its expertise in the Technology and Healthcare sectors, Keensight identifies the best investment opportunities in Europe and works closely with the management teams providing capital, strategic guidance and operational support. Keensight operates in more than 90 countries across the globe with a presence in Paris, London, Boston, and Singapore.

[www.keensight.com](http://www.keensight.com)

### **Press contacts**

#### **Symeres**

Aranda Rahbarkouhi, RA Marketing PR – [aranda@ramarketingpr.com](mailto:aranda@ramarketingpr.com)

#### **Keensight Capital**

Cindy Giraud, Communications Director – [cgiraud@keensight.com](mailto:cgiraud@keensight.com) +33 (0) 6 37 96 55 37

#### *Headland Consultancy*

Stephanie Ellis – [sellis@headlandconsultancy.com](mailto:sellis@headlandconsultancy.com) +44 (0) 73 1136 9804